Study

Study. The study entitled A Phase Ib study of Oraxol in combination with Ramucirumab in patients with Gastric, Gastro-esophageal, or Esophageal Cancers.

Study. Means the concomitant or sequenced administration of the Merck Compound and the Advaxis Compound (the "Phase I/II Trial"). More specifically, the Study is a Phase 1-2 Dose-escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination with Pembrolizumab (MK-3475) in Patients with Previously Treated Metastatic Castration-resistant Prostate Cancer.

Study. A Phase 1b/2, open-label, dose escalation study of the Syndax Compound in combination with the Merck Compound in patients with non-small cell lung cancer, with expansion cohorts in patients with non-small cell lung cancer and melanoma.

Study. ENCORE 603.

Study. The clinical investigation, management and/or research activities related to a particular human clinical trial, or similar Sponsor project conducted pursuant to the applicable Protocol or Sponsor instructions, including any management and oversight thereof.

Study. Each clinical trial to be conducted under this Agreement pursuant to an executed Study Plan for the concomitant or sequenced administration of the Regeneron Compound and the Replimune Compound as outlined in the Protocol that is attached to the applicable Study Plan, which Protocol may be amended by the JDC in accordance with Section 4.1. Each Study will be a Combination Clinical Trial in subjects with the tumor type identified in the applicable Study Plan.

Study. Each clinical trial to be conducted under this Agreement pursuant to a Study Plan involving a Product for the treatment of patients, as specifically described in the applicable Protocol; it being understood and agreed that the first Study is the Global Initial Study defined in Section 1.16 below.

Study. Each clinical trial to be conducted by Sponsor under this Agreement pursuant to an executed Study Plan involving the concomitant or sequenced administration of the Combination for the treatment of patients in the applicable Study Field, as more particularly described in the applicable Protocol.